Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?
Stefan Sleijfer and Gerrit Stoter*
Correspondence *Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Email g.stoter@erasmusmc.nl
This article has no abstract so we have provided the first paragraph of the full text.
The mainstay of treatment for advanced prostate cancer is androgen deprivation. The vast majority of patients respond with improvement of symptoms and reductions in PSA levels. However, all patients eventually develop progressive disease associated with a poor prognosis, with a median survival of 12–16 months.1, 2, 3, 4, 5 Chemotherapy has been extensively assessed in hormone-refractory prostate cancer. In randomized trials, mitoxantrone plus prednisone demonstrated improvement of pain and quality of life vs prednisone alone.1, 2, 3 Hence, this was deemed standard treatment in the US, although not so in Europe, since there was no survival benefit. Vinorelbine has been shown to yield a clinical benefit over corticosteroids alone similar to that achieved by mitoxantrone but again with no gain in survival.4
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.